
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IINNW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 25.78% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.12 | 52 Weeks Range 0.12 - 0.99 | Updated Date 06/14/2025 |
52 Weeks Range 0.12 - 0.99 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.03% | Return on Equity (TTM) -219.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 24090830 |
Shares Outstanding - | Shares Floating 24090830 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Inspira Technologies Oxy B.H.N. Ltd. Warrant
Company Overview
History and Background
Inspira Technologies Oxy B.H.N. Ltd. is focused on developing and marketing innovative respiratory support technology. The warrant represents the right to purchase shares of the company's stock under specific conditions. It aims to redefine acute respiratory care.
Core Business Areas
- Ventilator Development: Development of advanced respiratory support systems, including the ART device.
Leadership and Structure
The leadership team comprises individuals with experience in medical technology and business development. The organizational structure includes R&D, operations, and commercial teams.
Top Products and Market Share
Key Offerings
- ART (Augmented Respiration Technology) System: A respiratory support system designed to minimize the need for invasive mechanical ventilation. It directly oxygenates blood. Market share data unavailable due to pre-commercialization. Competitors include traditional ventilator manufacturers such as Medtronic (MDT) and Philips (PHG).
Market Dynamics
Industry Overview
The respiratory care market is driven by the increasing prevalence of respiratory diseases and the need for advanced ventilation technologies.
Positioning
Inspira Technologies aims to disrupt the market with its ART system, offering a less invasive alternative to traditional mechanical ventilation. Focus is on acute respiratory failure management.
Total Addressable Market (TAM)
The global respiratory care devices market is estimated at tens of billions of dollars. Inspira is positioned to capture a segment by addressing unmet needs in early-stage respiratory support.
Upturn SWOT Analysis
Strengths
- Innovative ART technology
- Potential to reduce invasive ventilation
- Focus on unmet clinical needs
Weaknesses
- Pre-commercialization stage
- Limited operating history
- Reliance on regulatory approvals
- Cash burn rate
- Dilution via warrant excercise
Opportunities
- Expanding respiratory care market
- Partnerships with hospitals and healthcare providers
- Regulatory approvals and clearances
- Geographic expansion
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial risks
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Philips (PHG)
- Getinge (GETI.ST)
Competitive Landscape
Inspira faces strong competition from established medical device companies with significant resources and market presence. Inspira's competitive advantage lies in its innovative ART technology, but it needs to demonstrate clinical and commercial success to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: No revenue has been booked to date.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of the ART system. Analyst estimates vary widely due to the speculative nature of the company's prospects.
Recent Initiatives: Recent initiatives include advancing clinical trials for the ART system, securing regulatory approvals, and establishing partnerships for commercialization.
Summary
Inspira Technologies is a speculative investment opportunity focused on developing innovative respiratory support technology. Its potential lies in its ART system, which aims to reduce the need for invasive ventilation, but it faces significant risks due to its pre-commercialization stage, competition, and regulatory hurdles. Future success depends on successful clinical trials and commercialization, which makes this investment high-risk, high-reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspira Technologies Oxy B.H.N. Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-14 | Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://inspira-technologies.com |
Full time employees 37 | Website https://inspira-technologies.com |
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.